Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (Lancet 2019, 2019-04-06: The 2019 EBCTCG dose-dense meta-analysis: 26 trials, 37,298 women. Shortening the interval between cycles or giving drugs sequentially reduced 10-year recurrence and breast cancer death without raising non-cancer mortality.
Increasing the dose intensity of adjuvant chemotherapy by shortening the interval between treatment cycles, or by giving individual drugs sequentially rather than giving the same drugs concurrently, moderately reduces the 10-year risk of recurrence and death
Abstract (INTERPRETATION)
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (Lancet 2019, 2019-04-06: The 2019 EBCTCG dose-dense meta-analysis: 26 trials, 37,298 women. Shortening the interval between cycles or giving drugs sequentially reduced 10-year recurrence and breast cancer death without raising non-cancer mortality. Funding: Cancer Research UK and UK Medical Research Council. Open access CC BY 4.0. Drugs: anthracycline/taxane regimens; makers not named. Comparator: same drugs at standard 3-week intervals or given concurrently. Reported recurrence reductions: 28.1% vs 31.3% (RR 0.87) for sequential vs concurrent; 30.4% vs 35.0% (RR 0.82) where both shortening and sequencing were tested. PMC6451189. Study type: review.
